ORPHA — Orphazyme A/S Share Price
0.000.00%
Last trade - 00:00- DKK36.97m
- DKK25.70m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.63 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.6 | ||
| Price to Tang. Book | 2.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -189.87% | ||
| Return on Equity | -94.35% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | n/a | n/a | n/a | n/a | n/a | 4,019 | 5,958 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +48.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
Directors
- Georges Gemayel CHM (61)
- Christophe Bourdon CEO
- Bo Hansen VCH (63)
- Anders Fink Vadsholt CFO (47)
- Thomas Kirkegaard Jensen CSO
- Thomas Blaettler OTH
- Martin Bonde DRC
- Stephanie Okey DRC
- Sten Verland DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 19th, 2009
- Public Since
- November 17th, 2017
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 35,312
- Address
- Ole Maaloees Vej 3, Copenhagen N, KOEBENHAVN, 2200
- Web
- https://www.orphazyme.com/
- Phone
- Auditors
- KPMG
Upcoming Events for ORPHA
Orphazyme A/S Annual Shareholders Meeting
Half Year 2024 Orphazyme A/S Earnings Release
Similar to ORPHA
Genmab A/S
OMX Nordic Exchange - Copenhagen
Gubra A/S
OMX Nordic Exchange - Copenhagen
ViroGates A/S
OMX Nordic Exchange - Copenhagen
Zealand Pharma A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the Orphazyme A/S share price?
As of Today at 19:16 UTC, shares in Orphazyme A/S are trading at DKK1,047.00. This share price information is delayed by 15 minutes.
How has the Orphazyme A/S share price performed this year?
Shares in Orphazyme A/S last closed at DKK1,047.00 and the price had moved by +32.53% over the past 365 days. In terms of relative price strength the Orphazyme A/S share price has outperformed the FTSE Global All Cap Index by +24.42% over the past year.
What are the analyst and broker recommendations for Orphazyme A/S?
The overall consensus recommendation for Orphazyme A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Orphazyme A/S dividend yield?
Orphazyme A/S does not currently pay a dividend.
Does Orphazyme A/S pay a dividend?
Orphazyme A/S does not currently pay a dividend.
When does Orphazyme A/S next pay dividends?
Orphazyme A/S does not currently pay a dividend.
How do I buy Orphazyme A/S shares?
To buy shares in Orphazyme A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orphazyme A/S?
As of the previous close price of DKK1,047.00, shares in Orphazyme A/S had a market capitalisation of DKK36.97m.
Where are Orphazyme A/S shares listed?
Here are the trading details for Orphazyme A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: ORPHA
What kind of share is Orphazyme A/S?
Based on an overall assessment of its quality, value and momentum Orphazyme A/S is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orphazyme A/S share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Orphazyme A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orphazyme A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -1.01%.
As of the last closing price of DKK1,047.00, shares in Orphazyme A/S were trading -6.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orphazyme A/S PE Ratio?
The Orphazyme A/S PE ratio based on its reported earnings over the past 12 months is 16.63. The shares last closed at DKK1,047.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orphazyme A/S?
Orphazyme A/S' management team is headed by:
- Georges Gemayel - CHM
- Christophe Bourdon - CEO
- Bo Hansen - VCH
- Anders Fink Vadsholt - CFO
- Thomas Kirkegaard Jensen - CSO
- Thomas Blaettler - OTH
- Martin Bonde - DRC
- Stephanie Okey - DRC
- Sten Verland - DRC